Physician profile
Errol Rushovich
NPI 1184664955
$4,295.12
in general payments reported to CMS, 2019-2025
31 companies · $209 in 2025
The $209 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,519 · 2020: $708 · 2021: $728 · 2022: $258 · 2023: $579 · 2024: $293 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,003 · Long Term Medical Supply Or Device Loan: $59.94 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.92 |
| Long Term Medical Supply Or Device Loan | $59.94 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $594.68 | 2019-2024 | Synthroid |
| Lilly USA, LLC | $572.85 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Sanofi-Aventis U.S. LLC | $421.68 | 2019-2022 | |
| Novo Nordisk INC | $388.02 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $270.95 | 2019-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Dexcom, INC. | $231.05 | 2019-2023 | Dexcom G6 Transmitter |
| Amgen INC. | $223.10 | 2019-2020 | |
| Radius Health, INC. | $146.13 | 2019-2024 | Tymlos |
| Merck Sharp & Dohme LLC | $141.85 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $126.24 | 2020-2025 | Unithroid |
| Tandem Diabetes Care, INC. | $123.15 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Antares Pharma, INC. | $105.29 | 2019-2020 | |
| Valeritas, INC. | $102.69 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.85 | 2019-2025 | Jardiance |
| Mannkind Corporation | $96.54 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $95.58 | 2019-2020 | |
| Insulet Corporation | $94.32 | 2019-2021 | |
| Beta Bionics, INC. | $88.48 | 2023 | Ilet Bionic Pancreas |
| Janssen Pharmaceuticals, INC | $58.13 | 2019-2020 | |
| Becton, Dickinson and Company | $49.98 | 2019 | |
| Alexion Pharmaceuticals, INC. | $40.28 | 2024 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $37.97 | 2021 | |
| Shire North American Group INC | $34.44 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $24.06 | 2019 | |
| Corcept Therapeutics | $22.18 | 2021 | |
| Cequr Corporation | $19.29 | 2024 | Cequr Simplicity |
| Medtronic Minimed, INC. | $19.26 | 2020 | |
| Gilead Sciences, INC. | $17.76 | 2019 | |
| Amarin Pharma, INC. | $17.76 | 2019 | |
| Companion Medical, INC. | $16.52 | 2019 | |
| Medtronic, INC. | $14.04 | 2023 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Errol Rushovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.